Dr. Anjali Vaidya, Director of the Advanced Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension Program at Temple University Hospital, shared her insights with Healio regarding the FDA’s decision to accept a new supplemental biologics license application for priority review for Winrevair. This medication is intended for the treatment of adults suffering from advanced pulmonary arterial hypertension.
The announcement follows news that Temple University Hospital – Main Campus will cease Labor and Delivery services starting September 3. These services will be moved to a new hospital location.
